Epidemiologic International Day
Download
1 / 11

Click here to view ENDORSE slides - PowerPoint PPT Presentation


  • 375 Views
  • Updated On :

Epidemiologic International Day For the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting. Sponsored by an unrestricted educational grant from sanofi-aventis to the Center for Outcomes Research, University of Massachusetts Medical School.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Click here to view ENDORSE slides' - Gideon


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Slide1 l.jpg

Epidemiologic International Day

For the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting

Sponsored by an unrestricted educational grant

from sanofi-aventis to the Center for Outcomes Research,

University of Massachusetts Medical School


Unique strengths l.jpg
Unique Strengths

  • Cross-sectional cohort study

  • Multi-national perspective

  • Representative populations

    • Hospitals

    • Patients

  • National and worldwide estimates of VTE risk factors and prophylaxis use



35 participating countries l.jpg

Algeria

Australia

Bangladesh

Brazil

Bulgaria

Columbia

Czech Republic

Egypt

France

Germany

Greece

Gulf States

Russia

Saudi Arabia

Slovakia

Spain

Switzerland

Thailand

Tunisia

Turkey

UK

USA

Venezuela

35 Participating Countries

  • Hungary

  • India

  • Ireland

  • Israel

  • Italy

  • Mexico

  • Morocco

  • Pakistan

  • Poland

  • Portugal

  • Romania


Objectives l.jpg
Objectives

  • To identify patients at risk for venous thromboembolism (VTE) among medical and surgical patients hospitalized in representative hospitals throughout the world

  • To determine the proportion of at-risk hospital patients who receive effective types of VTE prophylaxis


Study design l.jpg
Study Design

  • Cross sectional, observational survey

    • Enroll patients at “a single point in time”

    • Actual enrollment may take one month

  • Multinational perspective

  • Representative hospitals in each country

  • Consecutive patients within pre-specified wards


Hospital inclusion criteria l.jpg
Hospital Inclusion Criteria

  • Acute care hospitals

  • Randomly selected from country-wide lists

  • More than 50 beds

  • General medical & surgical wards

  • At least one general surgical ward

  • Schedule elective major surgical cases

  • Agree to participate in ENDORSE


Endorse steering committee l.jpg
ENDORSE Steering Committee

Co-Chairs: Ander Cohen & Victor Tapson

Committee Members

Jean-Francois Bergmann France

Ander Cohen United Kingdom

Samuel Goldhaber United States

Ajay Kakkar United Kingdom

Victor Tapson United States

Director, Study Coordinating Center

Fred Anderson United States



Motivation for hospitals to participate l.jpg
Motivation for Hospitals to Participate

  • Provide investigator at each hospital a confidential summary report showing a local profile of DVT risk and prophylaxis use, benchmarked against the country

  • Reimburse for effort of local data abstractor Or

  • Provide a data abstractor contracted by a CRO


Endorse will overcome important limitations of improve l.jpg
ENDORSE will Overcome Important Limitations of IMPROVE

  • Multinational perspective

  • Representative

    • Hospitals

    • Both medical and surgical patients

  • Can be used to make national estimates

    • Magnitude of VTE risk in-hospitals

    • Gap between trial evidence and

      real-world practices in prophylaxis use


ad